论文部分内容阅读
1开发与上市厂商由德国ZentaisAG公司研制,2003年1月首次在中国上市。2适应证本品主要用于治疗乳腺癌、小细胞肺癌及慢性粒细胞白血病。3药理作用本品对多种动物和人肿瘤细胞株有细胞毒作用,其毒性与卡铂相似,主要为骨髓造血抑制。肾毒性较低,体内外试验均表现出致突变作用。静脉注射后,血清中游离铂的血药浓度时间曲线与总铂基本相同,在血液循环中没有或很少有代谢物存在。铂的两种立体异构体曲线也完全相同。用药患者的血清总铂和游离铂的浓度时间曲线,在1小时内相似,11个小时后,血液循环中约25%的总铂与血清蛋白结合。本品主要经肾脏排泄。
1 Developed and marketed by the German company ZentaisAG company, January 2003 for the first time in China. 2 indications This product is mainly used for the treatment of breast cancer, small cell lung cancer and chronic myeloid leukemia. 3 pharmacological effects The goods on a variety of animal and human tumor cell lines have cytotoxicity, its toxicity and carboplatin similar to the main inhibition of bone marrow hematopoiesis. Nephrotoxicity is low, both in vivo and in vitro tests showed mutagenic effects. After intravenous injection, serum free platinum plasma concentration time curve with the total platinum is basically the same, no or little metabolites in the blood circulation exists. Platinum two stereoisomers the same curve. Serum total and free platinum concentration time profiles of treated patients were similar within 1 hour and about 25% of total platinum in blood circulation bound to serum proteins after 11 hours. This product is mainly excreted by the kidneys.